Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma. (July 2017)

• Record Type: Journal Article
• Authors: Sorigue, Marc; Sancho, Juan-Manuel; Pineda, Alberto; Garcia, Olga; Lopez, David; Moreno, Miriam; Tapia, Gustavo; Batlle, Montse; Ferra, Christelle; Vives, Susanna; Ibarra, Gladys; Feliu, Evarist; Ribera, Josep-Maria
• Is Part Of: Leukemia research. Volume 58(2017:Jul.)
• Page Start: 98
• Page End: 101
• Publication Date: 2017-07
• Subjects: Nephrotoxicity -- Lymphoma -- Survival -- Autologous stem cell transplantation -- Platinum -- ESHAP; Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2017.05.001
• Languages: English
• ISSNs: 0145-2126

Abstract

Highlights: We examined the incidence and impact of ESHAP nephrotoxicity in lymphoma patients. Nephrotoxicity was more common in outpatients than inpatients (14/39 vs. 4/35). Patients with renal failure at the time of ASCT had an inferior overall survival. Outpatient administration of ESHAP may not be optimal for all patients. Abstract: Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.